NVCR News and Press, NovoCure Limited From 03/01/23

Novocure ( NASDAQ: NVCR ) said its device Optune will get reimbursement and was available with temozolomide (TMZ) in France to treat adult patients with newly diagnosed glioblastoma (GBM), a type of brain cancer. The company noted that the order registering Optune on th...

Optune is now available as a treatment for newly diagnosed glioblastoma patients in France Novocure (NASDAQ:NVCR) today announced the reimbursement and availability of Optune together with temozolomide (TMZ) for the treatment of adult patients with newly diagnosed glioblastoma (GBM) in ...

Final data from the METIS study anticipated in 2024 Novocure (NASDAQ: NVCR) today announced that the final patient has enrolled in the pivotal METIS study evaluating the efficacy of Tumor Treating Fields (TTFields) therapy following stereotactic radiosurgery (SRS) for treatment of patie...

Shares of the novel oncology company NovoCure (NASDAQ: NVCR) are trading lower today following the company's 2022 fourth-quarter and full-year results release this morning. Specifically, the Tumor Treating Fields product (TTFields) pioneer's stock was down by a hefty 7.36% on heavy volume...

Novocure Limited (NVCR) Q4 2022 Results Earnings Conference Call February 23, 2023, 08:00 AM ET Company Participants Ingrid Goldberg - Vice President of Investor Relations William Doyle - Executive Chairman Asaf Danziger - Chief Executive Officer Ashley Cordova - C...

Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q4 2022 Earnings Call Feb 23, 2023 , 8:00 a.m. ET Ingrid Goldberg Continue reading For further details see: NovoCure (NVCR) Q4 2022 Earnings Call Transcript

The following slide deck was published by NovoCure Limited in conjunction with their 2022 Q4 earnings call. For further details see: NovoCure Limited 2022 Q4 - Results - Earnings Call Presentation

NovoCure press release ( NASDAQ: NVCR ): Q4 GAAP EPS of -$0.36 misses by $0.07 . Revenue of $128.43M (-3.6% Y/Y) beats by $1.23M . The United States, EMEA and Japan contributed $98.6 million, $17.0 million, and $7.9 million in quarterly net revenues, resp...

Dr. Ocean, a medical oncologist and Associate Professor of Clinical Medicine at Weill Cornell Medicine, brings decades of experience in oncology to Novocure Novocure (NASDAQ: NVCR) today announced that Allyson J. Ocean, M.D., has been elected to Novocure’s Board of Directors. ...

Full year 2022 net revenues of $538 million and fourth quarter net revenues of $128 million Pivotal LUNAR study in non-small cell lung cancer met primary overall survival endpoint and a key secondary overall survival endpoint Novocure completes enrollment of pivotal PANOVA-3 study...